Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track

Zura Bio Ltd

Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.
R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.
Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.
Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zura Bio Ltd reported full year ended December 31, 2025 results: net income Net loss was $68.7 million for the year ended December 31, 2025, EPS $(1.06) per basic and diluted share.

Period: full year ended December 31, 2025
Net income: Net loss was $68.7 million for the year ended December 31, 2025
EPS: $(1.06) per basic and diluted share
Result: reported results

Exact text from the filing

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-26-032077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.